Primer: CANbridge Pharmaceuticals (1228 HK) - Mar 2026
CANbridge Pharmaceuticals is a biopharmaceutical company strategically focused on the high-growth rare disease market in China, with a mission...
196 Views
China Healthcare Weekly (Dec.9) - COVID Policy Update, Biotech Growth Curve, HKEX Chapter 18A Review
China further optimized COVID policy, so as to release risks in advance and recover ASAP. The growth curve of biotech is not linear. We reviewed...
589 Views
Pre-IPO Laekna (PHIP Updates) - Some Key Points Worth the Attention
Laekna's core products would face different challenges, which makes us hard to be optimistic about their prospects.As a biotech based on license-in...
584 Views
Pre-IPO Cutia Therapeutics (CUT HK) - Outlook Is Uncertain Due to Unique Pipeline Characteristics
Cutia need to clarify whether its positioning is to sell drugs or consumer products,as their strategies will be different. Cutia has to strengthen...
526 Views
Pre-IPO Beijing Continent Pharmaceuticals -Â The Orphan Drug Pioneer Needs to Expand Overseas
Despite promising orphan drug market, with no new drugs commercialized until 2024, Continent will face increasing competition/financial pressure....
688 Views